HUE063194T2 - FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások - Google Patents

FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások

Info

Publication number
HUE063194T2
HUE063194T2 HUE15807049A HUE15807049A HUE063194T2 HU E063194 T2 HUE063194 T2 HU E063194T2 HU E15807049 A HUE15807049 A HU E15807049A HU E15807049 A HUE15807049 A HU E15807049A HU E063194 T2 HUE063194 T2 HU E063194T2
Authority
HU
Hungary
Prior art keywords
fap
therapeutic agents
uses related
activated therapeutic
activated
Prior art date
Application number
HUE15807049A
Other languages
English (en)
Inventor
William Bachovchin
Hung-Sen Lai
David Sanford
Sarah Poplawski
Wengen Wu
Original Assignee
Bach Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bach Biosciences Llc filed Critical Bach Biosciences Llc
Publication of HUE063194T2 publication Critical patent/HUE063194T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE15807049A 2014-06-13 2015-06-15 FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások HUE063194T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462011989P 2014-06-13 2014-06-13
US201462051033P 2014-09-16 2014-09-16

Publications (1)

Publication Number Publication Date
HUE063194T2 true HUE063194T2 (hu) 2024-01-28

Family

ID=54834485

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15807049A HUE063194T2 (hu) 2014-06-13 2015-06-15 FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások

Country Status (15)

Country Link
US (5) US10245248B2 (hu)
EP (2) EP3154594B1 (hu)
JP (3) JP6744826B2 (hu)
CN (4) CN113956325A (hu)
CA (1) CA2952051C (hu)
DK (1) DK3154594T3 (hu)
ES (1) ES2951596T3 (hu)
FI (1) FI3154594T3 (hu)
HR (1) HRP20230854T1 (hu)
HU (1) HUE063194T2 (hu)
IL (2) IL249370B (hu)
PL (1) PL3154594T3 (hu)
PT (1) PT3154594T (hu)
SI (1) SI3154594T1 (hu)
WO (1) WO2015192123A1 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113956325A (zh) * 2014-06-13 2022-01-21 塔夫茨大学信托人 Fap激活的治疗剂以及其相关用途
WO2015192124A1 (en) 2014-06-13 2015-12-17 Trustees Of Tufts College Fap-activated therapeutic agents, and uses related thereto
WO2017189569A1 (en) * 2016-04-25 2017-11-02 Trustees Of Tufts College Multimediator dpp4 and fap inhibitors, and uses related thereto
KR20190084063A (ko) 2016-10-28 2019-07-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
CN110267659A (zh) 2016-12-08 2019-09-20 西奈山伊坎医学院 用于治疗cdk4/6介导的癌症的组合物和方法
ES2972577T3 (es) 2016-12-14 2024-06-13 Purdue Research Foundation Formación de imágenes y terapia dirigidas a la proteína de activación de fibroblastos (FAP)
DK3391914T3 (da) * 2017-04-21 2021-10-18 Safe Implant Tech Aps Guldpartikler til anvendelse i terapi til at forebygge eller mindske kapselkontraktur
WO2019154859A1 (en) * 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
US11472799B2 (en) * 2018-03-06 2022-10-18 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
CN108864250A (zh) * 2018-05-29 2018-11-23 北京大学 一种FAPα酶敏感的吉西他滨前体药物及其制备方法和应用
IL311536A (en) * 2018-06-04 2024-05-01 Tufts College Binder-drug conjugates activated in the microenvironment and their related uses
US11426472B2 (en) 2018-10-17 2022-08-30 Purdue Research Foundation Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis
CA3134491A1 (en) * 2019-04-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use
EP4003321A4 (en) * 2019-07-22 2024-01-03 Purdue Research Foundation MULTIVALENT FIBROBLAST TARGETED AGENTS AND METHODS OF USE
DE112021000828T5 (de) 2020-01-31 2022-12-15 Canon Kabushiki Kaisha Photoelektrische umwandlungsvorrichtung, photoelektrischesumwandlungssystem und bewegliches objekt
CN111233955B (zh) * 2020-02-28 2022-06-10 南京缘聚医药科技有限公司 一类噻唑酮甲酰胞嘧啶衍生物及其药物用途
WO2022026729A1 (en) * 2020-07-31 2022-02-03 The Johns Hopkins University Fap-activated compounds for treatment of cancer
WO2022094262A1 (en) * 2020-10-30 2022-05-05 Avacta Life Sciences Limited Fap-activated serum extended half-life therapeutic conjugates
JP2023554396A (ja) * 2020-12-17 2023-12-27 トラスティーズ オブ タフツ カレッジ Ｆａｐ活性化ラジオセラノスティクスおよび関連する使用
EP4308110A1 (en) * 2021-03-16 2024-01-24 Purdue Research Foundation Compounds targeting fibroblast-activation protein and methods of use thereof
CN113018450B (zh) * 2021-05-24 2021-08-06 潍坊中医药产业技术研究院 一种具有肿瘤细胞和肿瘤相关成纤维细胞双靶向功能的药物载体、制备方法及应用
CN113845563B (zh) * 2021-09-28 2024-02-20 遵义医药高等专科学校 一种FAPα酶激活式鬼臼毒素衍生物及其制备方法与应用
WO2024008833A1 (en) 2022-07-05 2024-01-11 Alex Zounek Prodrug kit for multi-pronged chemotherapy
WO2024102956A1 (en) * 2022-11-09 2024-05-16 Purdue Research Foundation Keto-amide-based fibroblast activation protein-targeted ligand linked to an imaging or therapeutic agent, compositions and methods of use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
GB9309663D0 (en) 1993-05-11 1993-06-23 Erba Carlo Spa Biologically active compounds
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5767242A (en) 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
KR100928878B1 (ko) 1998-03-19 2009-11-30 버텍스 파마슈티칼스 인코포레이티드 카스파제의 억제제
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
AU2001266853B2 (en) 2000-06-14 2005-02-17 Medarex, Inc. Prodrug compounds with an oligopeptide having an isoleucine residue
GB0027552D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
US20030055052A1 (en) 2000-11-10 2003-03-20 Stefan Peters FAP-activated anti-tumor compounds
US20020155565A1 (en) 2000-11-10 2002-10-24 Pilar Garin-Chesa FAP-activated anti-tumor compounds
US20030232742A1 (en) * 2000-11-10 2003-12-18 Stefan Peters FAP-activated anti-tumor compounds
EP1238678A1 (en) 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzyme-activated cytostatic conjugates with integrin ligands
ATE504315T1 (de) 2001-06-11 2011-04-15 Medarex Inc Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen
EP1333033A1 (en) 2002-01-30 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG FAP-activated anti-tumor compounds
US20040033957A1 (en) 2002-05-10 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg FAP-activated anti-tumor prodrugs
EP1506221A2 (en) 2002-05-10 2005-02-16 Boehringer Ingelheim Pharma GmbH & Co.KG Fap-activated anti-tumor prodrugs
US7375078B2 (en) 2004-02-23 2008-05-20 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
JP2008517917A (ja) * 2004-10-21 2008-05-29 アイジーエフ オンコロジー エルエルシー 癌を治療するための毒素および放射性核種結合ｉｇｆ−１受容体リガンド
WO2007087131A2 (en) 2006-01-05 2007-08-02 The Johns Hopkins University Peptide prodrugs
WO2008011157A2 (en) 2006-07-20 2008-01-24 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US20100184706A1 (en) 2007-03-20 2010-07-22 Bachovchin William W Fap-activated chemotherapeutic compounds, and methods of use thereof
US9597410B2 (en) * 2011-08-30 2017-03-21 Trustees Of Tufts College FAP-activated proteasome inhibitors for treating solid tumors
MX2014011240A (es) 2012-03-21 2014-10-15 Bayer Ip Gmbh Uso de (rs)-s-ciclopropil-s-(4-{[4-{[(1r, 2r)-2-hidroxi-1-metilpro pil]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)sulfoximida para el tratamiento de tumores especificos.
MX2015004703A (es) 2012-10-16 2015-10-12 Genspera Inc Composiciones cancerigenas inyectables.
AU2013344552B2 (en) 2012-11-16 2018-03-15 Xiaoling Chen Novel heterocyclic derivatives as modulators of kinase activity
PL2938360T3 (pl) * 2012-12-28 2020-05-18 Cobiores Nv Minimalnie toksyczne proleki
WO2015192124A1 (en) 2014-06-13 2015-12-17 Trustees Of Tufts College Fap-activated therapeutic agents, and uses related thereto
CN113956325A (zh) 2014-06-13 2022-01-21 塔夫茨大学信托人 Fap激活的治疗剂以及其相关用途
WO2016046778A2 (en) 2014-09-25 2016-03-31 Amgen Inc Protease-activatable bispecific proteins
WO2017173347A1 (en) 2016-04-01 2017-10-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Par2 mimetic peptides and uses thereof
WO2017189569A1 (en) 2016-04-25 2017-11-02 Trustees Of Tufts College Multimediator dpp4 and fap inhibitors, and uses related thereto

Also Published As

Publication number Publication date
CA2952051C (en) 2023-09-12
EP3154594A1 (en) 2017-04-19
WO2015192123A1 (en) 2015-12-17
IL291922A (en) 2022-06-01
EP3154594A4 (en) 2018-01-24
JP2022116203A (ja) 2022-08-09
CN106573073B (zh) 2021-09-28
JP6744826B2 (ja) 2020-08-19
JP7530111B2 (ja) 2024-08-07
SI3154594T1 (sl) 2023-10-30
CN113967258B (zh) 2024-07-02
US10245248B2 (en) 2019-04-02
US20220087971A1 (en) 2022-03-24
DK3154594T3 (da) 2023-08-14
EP3154594B1 (en) 2023-07-19
FI3154594T3 (fi) 2023-08-07
EP4299134A3 (en) 2024-03-27
HRP20230854T1 (hr) 2023-11-10
US12023316B2 (en) 2024-07-02
ES2951596T3 (es) 2023-10-23
CN106573073A (zh) 2017-04-19
IL249370A0 (en) 2017-02-28
JP7093912B2 (ja) 2022-07-01
CN113786495A (zh) 2021-12-14
PT3154594T (pt) 2023-08-17
EP4299134A2 (en) 2024-01-03
JP2017519753A (ja) 2017-07-20
CN113967258A (zh) 2022-01-25
US20170119901A1 (en) 2017-05-04
US20210275491A1 (en) 2021-09-09
CN113956325A (zh) 2022-01-21
JP2020183448A (ja) 2020-11-12
PL3154594T3 (pl) 2023-10-09
US20200016114A1 (en) 2020-01-16
US11033525B2 (en) 2021-06-15
US12053450B2 (en) 2024-08-06
US20210308090A1 (en) 2021-10-07
CA2952051A1 (en) 2015-12-17
IL249370B (en) 2022-06-01

Similar Documents

Publication Publication Date Title
HK1256383A1 (zh) 治療劑
IL249370A0 (en) Fap-enabled medical substances and related uses
IL250685A0 (en) Medicinal substance induces cytotoxicity
HK1243073A1 (zh) 治療性化合物及其用途
GB201512203D0 (en) Agents,uses and methods
GB201509893D0 (en) Therapeutic agents
GB201517263D0 (en) Therapeutic agents
GB201410816D0 (en) Therapeutic agents
SG11201608943VA (en) Substituted 4-phenylpiperidines, their preparaiton and use
GB201408673D0 (en) Medicaments,uses and methods
GB201512215D0 (en) Agents,uses and methods
GB201502412D0 (en) Therapeutic use
GB201410216D0 (en) Therapeutic
GB201410817D0 (en) Therapeutic agents
GB201410815D0 (en) Therapeutic agents
GB201608797D0 (en) Therapeutic use
GB201509885D0 (en) Therapeutic agents
GB201509888D0 (en) Therapeutic agents
GB201418809D0 (en) Therapeutic agents and uses thereof
GB201415062D0 (en) Therapeutic
EP3197470A4 (en) Cis-gnetin h and trans-gnetin h as therapeutic agents
GB201513299D0 (en) Therapeutic agents
GB201521767D0 (en) Therapeutic agents
PT3129398T (pt) Novos agentes médicos e usos dos mesmos
GB201409653D0 (en) Pyrrolobenzodiazepine therapeutic agents